Melanoma/Skin Cancers
Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
The abstract concludes:
Pembrolizumab, administered at 200 mg every 3 weeks for up to 1 year as adjuvant therapy, provided, at a 3-yr median follow-up, a sustained improvement in RFS, which was clinically meaningful, in resected high-risk stage III melanoma. This improvement was consistent across subgroups. In the overall population, the 3-yr cumulative incidence of distant metastasis being the first recurrence was 22.3% (pembrolizumab group) vs 37.3% (placebo group) (HR 0.55, 95% CI 0.44-0.69). Clinical trial information:
NCT02362594
—————————————————————————————————————————————————————————————————————————————
The abstract concludes:
This 5-year analysis confirms the long-term benefit of adjuvant D+T in pts with resected stage III
BRAFV600E/K–mutant melanoma. Clinical trial information:
NCT01682083
—————————————————————————————————————————————————————————————————————————————
The abstract concludes:
Neoadj I1N3 treatment induced a high pRR with tolerable toxicity. TLND was omitted in a major subset of pts, reducing surgical morbidity. Longer FU is needed to report safety and RFS when TLND is omitted in MPR pts. Clinical trial information:
NCT02977052
—————————————————————————————————————————————————————————————————————————————
The abstract concludes:
The first 2 doses of nivo + ipi appear to drive combo’s response efficacy and toxicity. Early radiographic imaging at week 6 may be able to identify pts who do not respond to combo dosing beyond dose 2. Randomized studies are planned to evaluate 1 dose of combo to see if efficacy is maintained with reduced toxicity. Clinical trial information:
NCT03122522
—————————————————————————————————————————————————————————————————————————————
The abstract concludes:
This is the largest prospective study of IPI 1mg/kg + PEMBRO, demonstrating significant antitumor activity and tolerability in MEL post-PD1 Ab. Clinical trial information:
NCT02743819
—————————————————————————————————————————————————————————————————————————————
The abstract concludes:
In pts resistant to PD1, IPI+PD1 has higher RR, longer survival, yet similar high grade tox than IPI alone. Predictive models of response & survival will help select pts for IPI+/-PD1 after progressing on PD1.
—————————————————————————————————————————————————————————————————————————————
The abstract concludes:
Lifileucel treatment results in a 36.4% ORR and mDOR was not reached at 17.0 months of median study follow up in a heavily pretreated metastatic melanoma patients with high baseline disease burden who progressed on multiple prior therapies, including anti-PD1 and BRAF/MEK inhibitors, if
BRAFv600 mutant. Clinical trial information:
NCT02360579
—————————————————————————————————————————————————————————————————————————————
The abstract concludes:
The trial demonstrates the feasibility of prospective clinical trials in MM patients with LMD. The combination of IT/ IV N was safe and well-tolerated, with no unexpected systemic or neurological toxicity. Final presentation will include results of LMD composite response assessment, comparative analysis of longitudinal CSF/blood samples to assess immunologic effects. Finally, the interim OS of the patients is encouraging, and supports further evaluation of IT administration of immunotherapy agents for pts with MM and LMD. Clinical trial information:
NCT03025256
—————————————————————————————————————————————————————————————————————————————
—————————————————————————————————————————————————————————————————————————————
Abstract from the clinical science symposium: